Month: November 2016
In vitro dissolution testing is a critical component of drug product development and is often used as a surrogate for in vivo performance. While the range of (USP) standard methods have been developed and tested for many years, no single dissolution test or apparatus comprehensively maps the in vivo behaviour of the range of compound … Continued
Thinking Without BordersTM Developing Medicines that MatterTM These guiding principles fueled the creation of d3 Medicine. With a goal of revolutionizing the pharmaceutical paradigm to accelerate developing medicines that benefit society, combining d3 and Certara was a ‘no brainer.’ Delivering on our clients’ mission The d3 Medicine staff join Certara’s Strategic Consulting (CSC) division, which … Continued
PRINCETON, NJ – Nov. 10, 2016 – Certara today announced that the U.S. Environmental Protection Agency (EPA) is using its Simcyp Population-based Simulator to support the Agency’s high-throughput toxicity testing program.
PRINCETON, NJ – Nov. 9, 2016 – Certara announced that it will be chairing three sessions and participating in six more at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exposition.
In vitro-in vivo correlation (IVIVC) is an important, predictive mathematical tool in drug development, used to enhance product and process understanding with the ultimate goal of ensuring consistent performance throughout the product’s life cycle.
The Phoenix WinNonlin Validation Suite is a desktop application that provides objective evidence of Phoenix WinNonlin functionality and streamlines the validation process through the use of automated tests accessed through a graphical user interface and validation document templates.